Department of Medical Oncology, Tata Memorial Hospital, HBNI, Mumbai, India.
Department of Head and Neck Surgery, Tata Memorial Hospital, HBNI, Mumbai, India.
Eur J Surg Oncol. 2020 Jun;46(6):1052-1058. doi: 10.1016/j.ejso.2020.01.019. Epub 2020 Jan 15.
Studies reporting outcomes of salvage surgery in locally advanced head and neck squamous cell carcinoma (LAHNSCC) have inherent biases like biological and temporal selection. Our study considered all patients deemed fit for salvage surgery and compared to those who underwent surgery versus those who refused it thus throwing light on the real world benefit of salvage surgery.
This was a post hoc analysis of a phase 3 randomized trial conducted between 2012 and 2018. Out of 536 LAHNSCC patients randomised in the study, 113 patients had residual disease or recurrent disease and were planned for salvage surgery in a multidisciplinary clinic. Patients were divided into 2 cohorts for comparison, willing for salvage surgery (n = 91) and unwilling for salvage surgery(n = 22). The primary endpoint was overall survival.
The median follow up was 28.7 months (95%CI 23.9-33.5 months). Out of the 91 patients who were willing for salvage surgery, 78 underwent same. The median survival in cohort of patients willing for salvage surgery was 22.0 months (95%CI 10.1-33.9) while it was 9.7 months (95%CI 6.6-12.8) in patients who were unwilling for salvage surgery (HR = 0.262 95%CI HR 0.147-0.469, p = 0.000).
Salvage surgery leads to a substantial improvement in outcomes in head and neck cancers and should be the de facto standard of care in patients who are eligible for the same.
报道局部晚期头颈部鳞状细胞癌(LAHNSCC)挽救性手术结果的研究存在固有偏倚,如生物学和时间选择。我们的研究考虑了所有被认为适合挽救性手术的患者,并将其与接受手术的患者与拒绝手术的患者进行比较,从而揭示了挽救性手术的实际获益。
这是一项 2012 年至 2018 年进行的 3 期随机试验的事后分析。在该研究中,536 例 LAHNSCC 患者随机分组,其中 113 例患者有残留疾病或复发性疾病,在多学科诊所计划行挽救性手术。患者分为 2 个队列进行比较,愿意接受挽救性手术(n=91)和不愿意接受挽救性手术(n=22)。主要终点是总生存期。
中位随访时间为 28.7 个月(95%CI 23.9-33.5 个月)。在 91 例愿意接受挽救性手术的患者中,有 78 例接受了挽救性手术。愿意接受挽救性手术的患者队列的中位生存期为 22.0 个月(95%CI 10.1-33.9),而不愿意接受挽救性手术的患者的中位生存期为 9.7 个月(95%CI 6.6-12.8)(HR=0.262 95%CI HR 0.147-0.469,p=0.000)。
挽救性手术可显著改善头颈部癌症患者的预后,应成为符合条件患者的标准治疗方法。